Belite Bio: Wan-Shan Chen exercises 13,796 stock options

After the exercise, Chen directly held 37,259 ordinary shares, while the reported option position was 0.

Rhea-AI Filing Summary

BELITE BIO, INC. (BLTE) director Wan-Shan Chen exercised options to acquire 13,796 ordinary shares on September 24, 2026, at an exercise price of $0.4386 per share. Chen's direct ordinary-share holdings were 37,259 following the exercise; the reported option position following the transaction was 0.

Insider Trade Summary

13,796 shares exercised/converted

Exercise 2 txns

Insider Chen Wan-Shan

Role Director

Type	Security	Shares	Price	Value
In-the-Money Exercise	Stock Option (right to buy)	13,796	$0.00	$0.00
In-the-Money Exercise	Ordinary Share	13,796	$0.4386	$6K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Ordinary Share — 37,259 shares (Direct)

Key Figures

Options exercised: 13,796 options Exercise price: $0.4386 per share Ordinary shares acquired: 13,796 shares +2 more

5 metrics

Options exercised 13,796 options September 24, 2026

Exercise price $0.4386 per share Option exercise on September 24, 2026

Ordinary shares acquired 13,796 shares September 24, 2026

Direct ordinary shares following transaction 37,259 shares Following the September 24, 2026 exercise

Options following transaction 0 options Reported following the September 24, 2026 transaction

Key Terms

Stock Option (right to buy), in-the-money derivative security, exercise price

3 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

in-the-money derivative security financial

"Exercise of in-the-money or at-the-money derivative security"

exercise price financial

"conversion_or_exercise_price: 0.4386"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BLTE shares did Wan-Shan Chen acquire, and at what exercise price?

Wan-Shan Chen acquired 13,796 ordinary shares through an option exercise at $0.4386 per share on September 24, 2026.

What was Wan-Shan Chen's direct BLTE share position after the option exercise?

Chen's direct ordinary-share holdings were 37,259 shares following the exercise on September 24, 2026. The reported option position following the transaction was 0.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 09:00 PM EDT Accepted by SEC EDGAR 10/30/2026 - 09:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chen Wan-Shan

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Share	09/24/2026		X		13,796	A	$0.4386	37,259	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.4386	09/24/2026		X			13,796	03/31/2026	12/22/2030	Ordinary Shares	13,796	$0	0	D

Explanation of Responses:

	/s/ Wan-Shan Chen	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)